BICYCLE THERAPEUTICS plc: management transactions · United States · SEC (Form 4)

About BICYCLE THERAPEUTICS plc

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company listed on the U.S. NASDAQ market under the ticker BCYC, in the United States. The company is developing a differentiated class of medicines based on its proprietary bicyclic peptide platform, branded as Bicycle® molecules. These fully synthetic, constrained peptides are designed to combine high-affinity binding, selectivity, and drug-like manufacturability, positioning the company at the intersection of targeted oncology, radiopharmaceuticals, and next-generation biologics. Founded in 2009 from scientific work by Sir Gregory Winter and Professor Christian Heinis, Bicycle Therapeutics has evolved from a platform-origin biotech into a pipeline-driven development company. It operates as a transatlantic organization, with headquarters in Cambridge, UK, and important leadership and functional presence in Cambridge, Massachusetts, reflecting meaningful operational exposure in the United States. That dual footprint is relevant for U.S. investors because the company is US-listed, follows SEC disclosure standards, and has a significant U.S. corporate and scientific interface. The internal pipeline is centered on several key programs. Zelenectide pevedotin (formerly BT8009) targets Nectin-4 and is the company’s most advanced Bicycle Drug Conjugate (BDC®) asset. Nuzefatide pevedotin (formerly BT5528) targets EphA2, a historically difficult oncology target. BT7480 is a Bicycle Tumor-Targeted Immune Cell Agonist® designed to target Nectin-4 and agonize CD137. Bicycle is also building a radioconjugate franchise, including MT1-MMP and EphA2 imaging or therapeutic programs, with a long-term ambition to participate in radiopharmaceutical supply chains and potentially become an early mover in that niche. From a competitive standpoint, Bicycle Therapeutics is differentiated by its platform chemistry rather than by an approved commercial product. Its molecules are intended to bridge some of the limitations seen with antibodies and antibody-drug conjugates, especially around tissue penetration, specificity, and synthetic flexibility. At the same time, the company remains a high-risk development story: valuation is largely driven by clinical execution, biomarker strategy, regulatory optionality, and partnering success. Recent company updates in 2025 and 2026 point to a strategic reprioritization of resources toward the most promising assets, including nuzefatide pevedotin and the emerging Bicycle Radioconjugate pipeline. Management has also highlighted new supply-chain partnerships for radiopharmaceutical development and continued clinical readouts across the oncology portfolio. For investors, BCYC is best viewed as a platform-based biotech with meaningful scientific differentiation, but with binary readout risk typical of late-stage clinical development.